BioLine RX Ltd Asset Resilience Ratio
BioLine RX Ltd asset resilience ratio. BioLine RX Ltd (BLRX) has an Asset Resilience Ratio of 25.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does BioLine RX Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioLine RX Ltd (2006–2025)
Asset resilience ratio of BioLine RX Ltd from 2006 to 2025. This chart shows how BioLine RX Ltd's Asset Resilience Ratio has changed over time. See BioLine RX Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down BioLine RX Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is BioLine RX Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA8.39 Million | 25.24% |
| Total Liquid Assets | ILA8.39 Million | 25.24% |
Asset Resilience Insights
- Very High Liquidity: BioLine RX Ltd maintains exceptional liquid asset reserves at 25.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioLine RX Ltd Industry Peers by Asset Resilience Ratio
Compare BioLine RX Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
BioLine RX Ltd Asset Resilience Ratio by Year (2006–2025)
BioLine RX Ltd asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for BioLine RX Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.09% | ILA17.63 Million ≈ $47.26K |
ILA40.91 Million ≈ $109.69K |
+19.63pp |
| 2024-12-31 | 23.46% | ILA9.13 Million ≈ $24.47K |
ILA38.91 Million ≈ $104.31K |
-37.14pp |
| 2023-12-31 | 60.60% | ILA38.74 Million ≈ $103.86K |
ILA63.92 Million ≈ $171.38K |
+7.59pp |
| 2022-12-31 | 53.02% | ILA40.49 Million ≈ $108.57K |
ILA76.38 Million ≈ $204.78K |
-1.22pp |
| 2021-12-31 | 54.24% | ILA44.15 Million ≈ $118.35K |
ILA81.39 Million ≈ $218.21K |
+42.07pp |
| 2020-12-31 | 12.17% | ILA5.76 Million ≈ $15.43K |
ILA47.29 Million ≈ $126.78K |
-29.26pp |
| 2019-12-31 | 41.43% | ILA22.19 Million ≈ $59.50K |
ILA53.57 Million ≈ $143.61K |
-6.14pp |
| 2018-12-31 | 47.56% | ILA26.75 Million ≈ $71.71K |
ILA56.23 Million ≈ $150.76K |
-25.22pp |
| 2017-12-31 | 72.78% | ILA44.37 Million ≈ $118.96K |
ILA60.97 Million ≈ $163.45K |
-12.36pp |
| 2016-12-31 | 85.14% | ILA33.15 Million ≈ $88.88K |
ILA38.94 Million ≈ $104.39K |
+3.04pp |
| 2015-12-31 | 82.10% | ILA42.12 Million ≈ $112.92K |
ILA51.30 Million ≈ $137.54K |
+2.32pp |
| 2014-12-31 | 79.78% | ILA28.85 Million ≈ $77.36K |
ILA36.17 Million ≈ $96.96K |
+33.22pp |
| 2013-12-31 | 46.56% | ILA9.29 Million ≈ $24.90K |
ILA19.95 Million ≈ $53.48K |
+33.94pp |
| 2012-12-31 | 12.62% | ILA3.07 Million ≈ $8.22K |
ILA24.31 Million ≈ $65.17K |
-46.29pp |
| 2011-12-31 | 58.91% | ILA17.28 Million ≈ $46.34K |
ILA29.34 Million ≈ $78.65K |
+40.78pp |
| 2010-12-31 | 18.13% | ILA28.04 Million ≈ $75.17K |
ILA154.61 Million ≈ $414.51K |
-8.56pp |
| 2008-12-31 | 26.69% | ILA30.89 Million ≈ $82.81K |
ILA115.73 Million ≈ $310.26K |
+25.11pp |
| 2007-12-31 | 1.58% | ILA3.27 Million ≈ $8.78K |
ILA207.88 Million ≈ $557.33K |
-12.33pp |
| 2006-12-31 | 13.91% | ILA2.80 Million ≈ $7.50K |
ILA20.12 Million ≈ $53.95K |
-- |
About BioLine RX Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more